Epidemiological characteristics and clinical course of eyelid squamous cell carcinoma patients from a large tertiary centre between 2009 and 2020.
epidemiology
eye lids
neoplasia
Journal
The British journal of ophthalmology
ISSN: 1468-2079
Titre abrégé: Br J Ophthalmol
Pays: England
ID NLM: 0421041
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
received:
11
09
2020
revised:
10
02
2021
accepted:
14
02
2021
pubmed:
14
3
2021
medline:
26
7
2022
entrez:
13
3
2021
Statut:
ppublish
Résumé
To assess epidemiological tumour features, risk factors, clinical management and outcome of eyelid squamous cell carcinoma (SCC) and changes thereof. Furthermore, we searched for validating predictors of the American Joint Committee on Cancer (AJCC) 8 classification system. We evaluated data of 117 patients with histologically proven eyelid SCC at a large tertiary German university centre between January 2009 and March 2020. This retrospective, monocentric analysis included descriptive statistics and non-parametric tests (p<0.05). Histologically controlled excision and follow-up was performed in 88 (75.2%) patients. In the remaining patients with higher T-category, individual adjuvant therapy combinations were initiated. We found higher numbers of nodal metastasis and recurrence for male patients and higher T-category (p=0.035, p=0.008 and p=0.001, p<0.001). Recurrence rates proved higher for patients with multiple lesions (p=0.008). Disease-specific survival (DSS) was 95.7% at 2 and 94.9% at 5 years of follow-up. Six patients (5.1%) died from eyelid SCC with nodal metastasis and higher T-category being negative prognostic factors (p<0.001 and p=0.009). Mortality was associated with tumour location in the medial upper eyelid, nodal metastasis being more frequent (p=0.001 and p=0.009) and tumour of the lower eyelid alone as positive predictor (p=0.012). T category differed in 34 (29.1%) patients when comparing AJCC 7 and 8 (p<0.001). Changes in T category as per the AJCC 8 classification resulted in better prediction of DSS (p=0.024). Special attention should be paid to male patients, tumour location in the upper medial eyelid and lymph node diagnostics. Prediction of DSS proved superior as per the AJCC 8 staging system.
Sections du résumé
BACKGROUND/AIMS
To assess epidemiological tumour features, risk factors, clinical management and outcome of eyelid squamous cell carcinoma (SCC) and changes thereof. Furthermore, we searched for validating predictors of the American Joint Committee on Cancer (AJCC) 8 classification system.
METHODS
We evaluated data of 117 patients with histologically proven eyelid SCC at a large tertiary German university centre between January 2009 and March 2020. This retrospective, monocentric analysis included descriptive statistics and non-parametric tests (p<0.05).
RESULTS
Histologically controlled excision and follow-up was performed in 88 (75.2%) patients. In the remaining patients with higher T-category, individual adjuvant therapy combinations were initiated. We found higher numbers of nodal metastasis and recurrence for male patients and higher T-category (p=0.035, p=0.008 and p=0.001, p<0.001). Recurrence rates proved higher for patients with multiple lesions (p=0.008). Disease-specific survival (DSS) was 95.7% at 2 and 94.9% at 5 years of follow-up. Six patients (5.1%) died from eyelid SCC with nodal metastasis and higher T-category being negative prognostic factors (p<0.001 and p=0.009). Mortality was associated with tumour location in the medial upper eyelid, nodal metastasis being more frequent (p=0.001 and p=0.009) and tumour of the lower eyelid alone as positive predictor (p=0.012). T category differed in 34 (29.1%) patients when comparing AJCC 7 and 8 (p<0.001). Changes in T category as per the AJCC 8 classification resulted in better prediction of DSS (p=0.024).
CONCLUSION
Special attention should be paid to male patients, tumour location in the upper medial eyelid and lymph node diagnostics. Prediction of DSS proved superior as per the AJCC 8 staging system.
Identifiants
pubmed: 33712477
pii: bjophthalmol-2020-317969
doi: 10.1136/bjophthalmol-2020-317969
pmc: PMC9340003
doi:
Substances chimiques
Transforming Growth Factor beta
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1057-1062Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Br J Ophthalmol. 2014 Apr;98(4):498-501
pubmed: 24429279
Ophthalmic Plast Reconstr Surg. 2019 Jan/Feb;35(1):38-41
pubmed: 29877957
Orbit. 2016;35(1):29-34
pubmed: 26636727
J Craniofac Surg. 2019 Jul;30(5):1516-1519
pubmed: 31299757
Ophthalmology. 1999 Apr;106(4):746-50
pubmed: 10201597
Dermatology. 1994;189(4):364-7
pubmed: 7873821
J Invest Dermatol. 1994 Jun;102(6):10S-13S
pubmed: 8006426
Eye (Lond). 2014 Aug;28(8):962-7
pubmed: 24858526
Med J Aust. 1986 Mar 3;144(5):235-9
pubmed: 3587093
Arch Ophthalmol. 1986 Jun;104(6):901-9
pubmed: 3718316
Surv Ophthalmol. 1986 May-Jun;30(6):349-65
pubmed: 3523806
Plast Reconstr Surg. 1966 Feb;37(2):100-4
pubmed: 5908191
Dermatol Surg. 2000 Jun;26(6):521-30
pubmed: 10848931
Ophthalmic Plast Reconstr Surg. 2002 Nov;18(6):430-5
pubmed: 12439056
Ophthalmology. 1997 Mar;104(3):479-84
pubmed: 9082276
Br J Ophthalmol. 2002 Oct;86(10):1161-5
pubmed: 12234899
Am J Surg. 1984 Oct;148(4):542-7
pubmed: 6486325
JAMA Ophthalmol. 2019 May 1;137(5):537-542
pubmed: 30869769
Ophthalmologe. 2006 Feb;103(2):124-8
pubmed: 16047150